A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.

Novo Nordisk, the Denmark-based pharmaceutical company that makes Ozempic and Wegovy, looks like it's being toppled ... Novo ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Families of children at Camp Mystic who died in the devastating floods in Texas last month made emotional testimonies and ...

Twice as many employers as last year say they are planning to pull back on filling jobs, according to a new Conference Board survey.

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...